13F filer · CIK 2006045
SymBiosis Capital Partners, LLC
BENTONVILLE, AR · filing since Q4 2025 · last filing May 12, 2026
Reported value
$52.8M
$-56.7M vs prior
Positions
6
New / sold out
1 / 6
Added / reduced
0 / 3
Turnover
6.7%
buys $5.4M · sells $67.4M
Top-10 weight
100.0%
Biggest buys vs Q4 2025
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Wave Life Sciences Ltd. | +750,000 | – | +$5.4M |
Biggest sells vs Q4 2025
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Verastem Inc | -2,000,000 | -100.0% | $-15.4M |
| Sold out | Aldeyra Therapeutics Inc | -2,555,000 | -100.0% | $-13.2M |
| Sold out | Precigen Inc | -3,000,000 | -100.0% | $-12.5M |
| Sold out | Nuvation Bio Inc | -1,250,000 | -100.0% | $-11.2M |
| Sold out | Aardvark Therapeutics, Inc. | -476,595 | -100.0% | $-6.3M |
| Sold out | Generation Bio Co | -665,000 | -100.0% | $-3.8M |
| Reduced | Rani Therapeutics Holdings, Inc. | -2,632,415 | -41.8% | $-1.9M |
| Reduced | Clene Nanomedicine Inc. | -339,401 | -44.0% | $-1.7M |
| Reduced | Inventiva S.A. | -246,000 | -9.5% | $-1.4M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q1 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Evommune, Inc.COM SHS | 1,280,778 | $29.4M | 55.80% |
| 2 | Inventiva S.A.ADS | 2,354,000 | $13.1M | 24.76% |
| 3 | Wave Life Sciences Ltd.SHS | 750,000 | $5.4M | 10.30% |
| 4 | Rani Therapeutics Holdings, Inc.COM CL A | 3,667,585 | $2.7M | 5.11% |
| 5 | Clene Nanomedicine Inc.COM NEW | 431,094 | $2.1M | 4.03% |
| 6 | Surrozen, Inc.*W EXP 08/01/203 | 150,000 | $2.4K | 0.00% |